Evidence map›Paper›PMID 30399369›Full record

ArticleTranslational research : the journal of laboratory and clinical medicine2019

A small molecule Hedgehog agonist HhAg1.5 mediated reprogramming breaks the quiescence of noninjured liver stem cells for rescuing liver failure.

Abhisek Mitra, Jun Yan, Liangfang Zhang, Shulin Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational research : the journal of laboratory and clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Stem cell-based therapeutic strategies for liver aging.Liver research (Beijing, China) · 2025
    Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Abhisek MitraDepartment of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jun YanDepartment of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Liangfang ZhangDepartment of Nanoengineering, University of California, San Diego, La Jolla, California.
Shulin LiDepartment of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: amitra@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USUniversity of California San Diego · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Pathway Specific Functional Biomarkers for the Early Detection of Liver CancerU01CA230690 · NCI · GEORGE WASHINGTON UNIVERSITY · PI MISHRA, LOPA, SHETTY, KIRTI · 2018 to 2022
$3.4M
Low Electric Field-Based Gene Delivery of IL-30 Gene Therapy for Liver InjuryR01DK102767 · NIDDK · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LI, SHULIN · 2015 to 2019
$1.8M
NCI NIH HHS P30 CA016672NCI NIH HHS U01 CA230690NIDDK NIH HHS R01 DK102767
6 · The paper itself

Abstract

Liver is the second most transplanted organ according to United network for organ sharing. Due to shortage of compatible donors, surgical difficulties, immunological hindrance, and high postoperative cost, stem cell therapy is an attractive substitute of liver transplant for millions of patients suffering from hepatic failure. Due to several technical limitations such as viral integration, inefficient differentiation, and adult phenotypes and epigenetic memory of fibroblasts, induced pluripotent stem cells, mesenchymal stem cells, or induced hepatocyte may not present a great clinical substitute for liver transplant. We pioneered a novel technology for robust expansion of quiescent liver stem cells (LSCs) from mice via utilizing of Hedgehog agonist HhAg1.5 for 3 weeks. These expanded LSCs retained stem-like properties after multiple passaging and differentiated to hepatocytes and cholangiocytes. Grafting of ex vivo expanded LSCs in Fah

Indexed as

AC133 AntigenAdult Stem CellsAnimalsBiliary TractCell DifferentiationHedgehog ProteinsHepatocytesLeukocyte Common AntigensLiverLiver FailureLongevityMiceMice, KnockoutRegenerative MedicineSmall Molecule LibrariesAC133 AntigenHedgehog ProteinsLeukocyte Common AntigensProm1 protein, mousePtprc protein, mouseSmall Molecule LibrariesFRG((fumarylacetoacetate hydrolase)  Fah(−/−)  Rag2(−/−) Il2rg(−/−))Hedgehog agonist 1.5HhAg1.5induced pluripotent stem cellsiPSCsliver stem cellsliver transplantLSCsLTmesenchymal stem cellsMSCs

Identifiers

PMID30399369
PMCPMC6372324
OpenAlexW2896979250

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.